WallStSmart
PASG

Passage Bio Inc

NASDAQ: PASG · HEALTHCARE · BIOTECHNOLOGY

$3.33
-0.60% today

Updated 2026-10-28

Market cap
$10.84M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-11.33
Dividend yield
—
52W range
$3 – $20
Volume
0.0M

WallStSmart proprietary scores

29
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
3.3
Quality
D
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-17.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75

Price targets

Analyst target
$15.50
+365.47%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy2 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -17.52 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-9.18M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-136.13M$-102.06M$-64.77M$-45.52M$-7.82M
EPS————$-11.33
Free cash flow$-123.48M$-78.41M$-47.99M$-31.51M$-9.18M
Profit margin—————

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
PASG$10.84M294.33.05.03.3—Avoid
LLY$1.12T769.310.05.06.0—Strong Buy
JNJ$615.87B574.78.52.75.5-83.05%Buy
ABBV$504.37B736.78.54.05.0-86.73%Strong Buy
UNH$360.32B626.76.04.75.5-25.92%Buy
MRK$360.08B364.04.52.05.0-73.68%Hold

Smart narrative

Passage Bio Inc trades at $3.33. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -17.52, it sits in the distress.

Frequently asked questions

What is Passage Bio Inc's stock price?

Passage Bio Inc (PASG) trades at $3.33.

Is Passage Bio Inc overvalued?

Passage Bio Inc carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Passage Bio Inc (PASG)?

The 12-month analyst consensus target is $15.50, about 365.5% above the current $3.33. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Passage Bio Inc's Altman Z-Score is -17.52, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio—
ROE-320.59%
Beta1.39
50D MA$4.39
200D MA$6.59
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M

Performance

1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—